T2DM model mice treated with the DNA methyltransferase 1 inhibitor aurintricarboxylic acid (ATA) show reduced activation of DNA methyltransferase 1 in pancreatic β-cells and increased expression of NR4A1 and decreased blood glucose [90]. This evidence concerns the gene NR4A1 and type 2 diabetes mellitus.